An interventional study of QISENG and PLACEBO in Breast Cancer and Fatigue, sponsored by Centre Francois Baclesse. Recruiting at 10 sites in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-01.
Sponsored by Centre Francois Baclesse · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Breast Neoplasms by Centre Francois Baclesse — 4 open to participants now, 5 under way, none of them phase 3. Breast Neoplasms · Centre Francois Baclesse.
Among the 23 studies in Breast Neoplasms by Centre Francois Baclesse, this one is the 3rd largest by planned enrollment of the 19 interventional ones that give a count, is one of 2 that started in 2022, is one of 12 with no phase, and was the 18th registered.
14,848 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.
Browse Breast Neoplasms studies →4 of the 23 studies in Breast Neoplasms by Centre Francois Baclesse are open now, in 1 country. Recruiting first, the newest first:
Centre Francois Baclesse · Sites in France
Ages 30–50 · Women only · Healthy volunteers
Centre Francois Baclesse · Sites in France
Ages 18 mo+ · Women only
Centre Francois Baclesse · Sites in France
Ages 45–65 · Women only · Healthy volunteers
By country, each count listing its studies:
Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 2
First in 2007; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 354 is above the median of 72 across 10,921 interventional studies indexed under Breast Neoplasms.
Median enrollment 75 across the 19 interventional studies, 89 across the 4 observational. Of the 18 that completed or were terminated, 4 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
Centre Francois Baclesse is the lead sponsor of 110 studies on the registry; 26 are open to participants now.
2 of the studies in Breast Neoplasms by Centre Francois Baclesse that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05414357Centre Francois BaclesseImpact of Sleep Disturbance on Cognition and Quality of Life in Breast Cancer | 2027-03 |
| NCT05241405Centre Francois BaclesseEvaluation of the Impact of Taking American Ginseng for 8 Weeks on Fatigue in Patients Treated for Localized Breast or Gynecological Cancer | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 23 studies in Breast Neoplasms by Centre Francois Baclesse, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a multicenter randomized trial in breast cancer patients reporting cancer-related fatigue to evaluate the efficacy and safety of Qiseng® based on extract of American ginseng combined with vitamin C from extract of Camu Camu berries
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients with localized breast or gynecological cancer treated as curative and/or neoadjuvant chemotherapy and/or adjuvant radiotherapy. These treatments must have been completed within 6 months of inclusion.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
200 mg/capsule of P. quinquefolius extract, i.e. 30 mg of ginsenosides, associated with 30 mg of vitamin C extracted from Camu Camu berry
Dietary Supplement: QISENG
neutral microgranules of Qiseng® excipients without P. quinquefolius or Camu Camu extract
Dietary Supplement: PLACEBO
2 capsules/day for 8 weeks.
2 capsules/day for 8 weeks.
Fatigue score change [min :5; max:20]
The difference between the initial (inclusion) score and the best score based on EORTC QLQ-FA12 questionnaire (physical fatigue dimension) between assessments at 1 week (S9) and 4 weeks (S12) after the end of treatment) will be calculated
Time frame: After 1 week and 4 weeks after the end of treatment (so 8 weeks of treatment)
Other dimensions of fatigue [min :12; max:48]
Score of emotional fatigue, cognitive fatigue, global score, according to the EORTC QLQ-FA12 self-questionnaire
Time frame: after 4 weeks of treatment, after 8 weeks of treatment and 4 weeks after the end of treatment
The incidence of treatment-related adverse events
The incidence of treatment-related adverse events and the number of patients in whom at least one treatment-related adverse event occurred
Time frame: up to 8 weeks after the end of treatment
Quality of life level assessed by EORTC QLQ-C30 questionnaire
EORTC QLQ-C30 quality of life questionnaire scores
Time frame: 4 and 8 weeks of treatment and 4 weeks after the end of treatment
anxiety level
HADS anxiety and depression questionnaire scores
Time frame: after 4 and 8 weeks of treatment, and 4 weeks after the end of treatment
Cognitive function
Cognitive function dimensions, according to the FACT-Cog self-assessment questionnaire,
Time frame: after 4 and 8 weeks of treatment and 4 weeks after the end of treatment
Physical activity level
measured by the IPAQ questionnaire scores
Time frame: after 4 and 8 weeks of treatment, and again 4 weeks after the end of treatment
Sleep quality
measured by CAT-sleep questionnaire scores
Time frame: after 4 and 8 weeks of treatment and 4 weeks after the end of treatment
The level of acceptability of the treatment,
measured by the total number of times the treatment was taken
Time frame: over a period of 8 weeks
Plan to share: No
No publications or documents are linked to this record.
Started Sep 2022 (actual). Primary completion is estimated for Sep 2027, 60 months after the start.
Of 2,673 non-industry interventional studies with no phase under Breast Neoplasms, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 66. This study's planned 60 months is above that.
Counting every sponsor, half of 2,783 studies reached it within 33 months; a quarter within 15 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.